Home General Biotechnology

Drug Patent Expirations for June 2014

TradenameApplicantGeneric NamePatent NumberPatent Expiration
BETOPTIC PILOAlconbetaxolol hydrochloride; pilocarpine hydrochloride5,635,172Jun 3, 2014
LOCOID LIPOCREAMPrecision Dermathydrocortisone butyrate5,635,497Jun 3, 2014
ATACAND HCTAstrazenecacandesartan cilexetil; hydrochlorothiazide5,958,961Jun 6, 2014
NEVANACAlcon Pharms Ltdnepafenac5,475,034Jun 6, 2014
ILEVROAlcon Res Ltdnepafenac5,475,034Jun 6, 2014
EDARBIArbor Pharms Irelandazilsartan kamedoxomil5,958,961Jun 6, 2014
TAZORACAllergantazarotene6,258,830Jun 7, 2014
TAZORACAllergantazarotene5,914,334Jun 7, 2014
ACTONEL WITH CALCIUM (COPACKAGED)Warner Chilcottcalcium carbonate; risedronate sodium5,583,122*PEDJun 10, 2014
NAPRELANAlmatica Pharma Incnaproxen sodium5,637,320Jun 10, 2014
FROVAEndo Pharmsfrovatriptan succinate5,637,611Jun 10, 2014
ACTONELWarner Chilcott Llcrisedronate sodium5,583,122*PEDJun 10, 2014
ATELVIAWarner Chilcott Llcrisedronate sodium5,583,122*PEDJun 10, 2014
XELODAHoffmann La Rochecapecitabine5,472,949*PEDJun 14, 2014
HUMALOG MIX 50/50 KWIKPENLillyinsulin lispro protamine recombinant; insulin lispro recombinant5,461,031Jun 16, 2014
HUMALOG PENLillyinsulin lispro recombinant5,474,978Jun 16, 2014
HUMALOG MIX 50/50 KWIKPENLillyinsulin lispro protamine recombinant; insulin lispro recombinant5,747,642Jun 16, 2014
HUMALOGLillyinsulin lispro recombinant5,474,978Jun 16, 2014
HUMALOG MIX 75/25Lillyinsulin lispro protamine recombinant; insulin lispro recombinant5,474,978Jun 16, 2014
HUMALOG MIX 50/50Lillyinsulin lispro protamine recombinant; insulin lispro recombinant5,461,031Jun 16, 2014
HUMALOG MIX 75/25 KWIKPENLillyinsulin lispro protamine recombinant; insulin lispro recombinant5,461,031Jun 16, 2014
HUMALOG MIX 50/50Lillyinsulin lispro protamine recombinant; insulin lispro recombinant5,747,642Jun 16, 2014
HUMALOG MIX 75/25 KWIKPENLillyinsulin lispro protamine recombinant; insulin lispro recombinant5,747,642Jun 16, 2014
HUMALOG MIX 50/50 KWIKPENLillyinsulin lispro protamine recombinant; insulin lispro recombinant5,474,978Jun 16, 2014
HUMALOG MIX 75/25Lillyinsulin lispro protamine recombinant; insulin lispro recombinant5,461,031Jun 16, 2014
HUMALOG KWIKPENLillyinsulin lispro recombinant5,474,978Jun 16, 2014
HUMALOG MIX 75/25Lillyinsulin lispro protamine recombinant; insulin lispro recombinant5,747,642Jun 16, 2014
HUMALOG MIX 50/50Lillyinsulin lispro protamine recombinant; insulin lispro recombinant5,474,978Jun 16, 2014
HUMALOG MIX 75/25 KWIKPENLillyinsulin lispro protamine recombinant; insulin lispro recombinant5,474,978Jun 16, 2014
SOLARAZEFougera Pharmsdiclofenac sodium5,639,738Jun 17, 2014
SOLARAZEFougera Pharmsdiclofenac sodium5,929,048Jun 17, 2014
IMAGENTImcor Pharms Codimyristoyl lecithin; perflexane5,639,443Jun 17, 2014
SOLARAZEFougera Pharmsdiclofenac sodium5,852,002Jun 17, 2014
MARQIBO KITTalon Therapvincristine sulfate5,741,516Jun 20, 2014
MARQIBO KITTalon Therapvincristine sulfate5,814,335Jun 20, 2014
MARQIBO KITTalon Therapvincristine sulfate5,543,152Jun 20, 2014
ZEMPLARAbbvieparicalcitol5,587,497*PEDJun 24, 2014
YAZBayer Hlthcaredrospirenone; ethinyl estradiolRE37838Jun 30, 2014
BEYAZBayer Hlthcaredrospirenone; ethinyl estradiol; levomefolate calciumRE37564Jun 30, 2014
YAZBayer Hlthcaredrospirenone; ethinyl estradiolRE38253Jun 30, 2014
BEYAZBayer Hlthcaredrospirenone; ethinyl estradiol; levomefolate calciumRE37838Jun 30, 2014
ACOVAPfizerargatroban5,214,052Jun 30, 2014
YAZBayer Hlthcaredrospirenone; ethinyl estradiolRE43916Jun 30, 2014
BEYAZBayer Hlthcaredrospirenone; ethinyl estradiol; levomefolate calciumRE43916Jun 30, 2014
YAZBayer Hlthcaredrospirenone; ethinyl estradiolRE37564Jun 30, 2014
BEYAZBayer Hlthcaredrospirenone; ethinyl estradiol; levomefolate calciumRE38253Jun 30, 2014
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Maryland and Virginia unite at 2007 Mid-Atlantic Bio Conference

Go to paper

ABSTRACT:   

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Asian biotechnology innovation

Asian biotechnology innovation

My paper on global biopharmaceutical productivity has been published in the latest issue of Nature Biotechnology.

This paper is a refinement of my work ranking international biotechnology for Scientific American Worldview, and draws on the DrugPatentWatch database.

In this paper I investigate the locations of drug inventors, as measured by patents covering marketed drugs. The result, which may surprise many readers, is that the bulk of the innovation still occurs in the legacy pharma regions — Western Europe, the United States, and Japan.

I have many thoughts on why larger Asian countries like India, South Korea, and China demonstrate little innovation in biopharmaceuticals (and I’ve expressed these views at length in my talks, and here and here), and I have also published prescriptions for smaller nations.

Given the poor output of patents covering marketed drugs from countries such as China, one must ask whether vigorous pro-patenting policies (China leads the world in patent applications — but not in grants) are appropriate. Additionally, one must ask if Western metrics for innovation should be applied to other contexts.

To access the full paper (paywall), see http://www.nature.com/nbt/journal/v32/n6/full/nbt.2933.html

For more information on the DrugPatentWatch database, see http://www.DrugPatentWatch.com

Journal of Commercial BiotechnologyMassBio and the Journal of Commercial Biotechnology have partnered to provide MassBio members with free and discounted subscriptions.

  • New MassBio members can get a free 1 year digital subscription to the Journal of Commercial Biotechnology
  • Existing MassBio members can get a 20% discount on Journal of Commercial Biotechnology subscriptions

Members should contact editor@CommercialBiotechnology.com to activate their free subscription or to purchase a discounted subscription.

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

To discuss a partnership with your organization, contact editor@CommercialBiotechnology.com .

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Legal and regulatory update

Go to paper

ABSTRACT: The European Commission has launched a public consultation on its proposed amendments to the Medical Devices Directive (MDD) (Dir 93/42/EEC). The aim of the European Commission's proposals is to improve the coherence, transparency and effectiveness of the legislation governing medical devices in line with the recommendations of the report produced in 2002 by the European Commission's Medical Device Experts Group...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Susan Kling FinstonThis is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below.

India’s recent election has brought a decisive majority to the right-of-center BJP Party, carrying BJP leader Narendra Modi to the Prime Minister’s office. What will the decisive BJP Victory mean for the future of innovative life sciences in India? Will Prime Minister Modi re-invigorate commercial biotechnology in Delhi?

The State of Gujarat has long been a been a manufacturing and export powerhouse for generic pharmaceuticals, where “Gujarat contributes nearly 28 per cent to national pharmaceutical exports.” In contrast to the broader challenges facing bio-pharma growth in India, Gujarat has continued as a bright spot for pharmaceutical exports, enjoying double-digit growth over the last fiscal year. Long recognized as a manufacturing powerhouse, Gujarat has captured an outsize share – now exceeding 40% of India’s total generics turnover. 

During his 12-year tenure as Chief Minister of the State of Gujarat, Minister Modi identified the innovative life sciences as having great development potential, having seen the benefits to India’s southern states of Karnataka and Andhra Pradesh from the Information and Communications Technology (ICT) revolution. Then-Chief Minister Modi set out to to attract highly innovative life sciences companies to the State through seed funding programs as well as promotion of the sector at Vibrant Gujarat – a bi-annual pan-industrial congress attracting industry leaders from across India and abroad.

Established under the jurisdiction of the Gujarat State Biotechnology Mission (GSBTM) and administered by the Gujarat Venture Fund Limited (GVFL), the Gujarat Biotech Venture Fund (GBVF) provides seed funding to innovative companies registered in Gujarat. (Full disclosure: my biotech start-up, Amrita Therapeutics Public Limited, received initial seed funding under the GBVF that enabled the company to initiate R&D at the depths of the global economic crisis in early 2009.) I met Minister Modi at the 2009 Vibrant Gujarat  in Gandhinagar, and witnessed first hand the intensive efforts underway to support growth of Gujarat’s innovative biotech sector.

Now Prime Minister-elect Modi has the opportunity to ‘green light’ incentives to encourage home-grown biotech start-ups across the country, including:

  • Investment Tax Credits to encourage investment by VCs and Angel Investors in ‘high risk, high reward’ biotech discovery companies that require a substantial commitment of funds for a decade or more before commercial launch
  • Expansion of current Department of Biotechnology (DBT) industry partnership programs, with an orientation to support for cutting-edge, biotech ventures vs. established pharma manufacturers
  • Focus on regulatory excellence: Indian industry – and Indian’s own citizens – can only thrive in an environment with unquestionable Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP)
  • Collaborate closely with the International Conference on Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) to ensure that Indian clinical trials fully meet international standards and that Indian patients gain access to clinical research for indigenous innovative therapies and cures for cancer and other high priority public health threats

Beyond increasing access to early capital, the Indian Government also could do more specifically to promote innovative oncology research to address the growing public health threat of colorectal and other cancers for Indian nationals. In the U.S. and in India alike, biotechnology companies historically take root and multiply in clusters in close proximity with other biotech companies, research institutes, and incubation facilities that provide access to wet-labs and high-cost, sensitive equipment and other supplies — Establishment of focused research clusters for oncology R&D would bring long-term benefits.

The Indian electorate voted decisively for change and economic reforms to encourage the assimilation of new technologies for broader social and economic benefits. Time will tell whether Prime Minister-elect Modi will again focus efforts on biotechnology – beyond Gujarat’s borders – for the benefit of India and the world.

About the author:
President of Finston Consulting LLC since 2005, Susan works with innovative biotechnology and other clients ranging from start-up to Fortune-100, providing support for legal, transactional, policy and “doing business” issues. Susan has extensive background and special expertise relating to intellectual property and knowledge-economy issues in advanced developing countries including India and South Asia, Latin America and the Middle East North Africa (MENA) region. She also works with governments, and NGOs on capacity building and related educational programs through BayhDole25. Together with biotechnology pioneer Ananda Chakrabarty, she also is co-founder of Amrita Therapeutics Ltd., an emerging biopharmaceutical company based in India with cancer peptide drugs entering in vivo research. Previous experience includes 11 years in the U.S Foreign Service with overseas tours in London, Tel Aviv, and Manila and at the Department of State in Washington DC. For more information on latest presentations and publications please visit finstonconsulting.com.

Journal of Commercial BiotechnologyBIOTECanada and the Journal of Commercial Biotechnology have partnered to provide BIOTECanada members with free and discounted subscriptions.

    • New BIOTECanada members can get a free 1 year digital subscription to the Journal of Commercial Biotechnology
    • Existing BIOTECanada members can get a 20% discount on Journal of Commercial Biotechnology subscriptions

Members should contact editor@CommercialBiotechnology.com to activate their free subscription or to purchase a discounted subscription.

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

To discuss a partnership with your organization, contact editor@CommercialBiotechnology.com .

Stem cells are a rapidly developing technology area. The pace of scientific and clinical progress is accompanied by new patents, which can secure technology for innovators, and require careful observation by others to avoid infringement.

After discussions with Christian Walker, a colleague and entrepreneur in the stem cell space, I have launched StemCellPatentWatch to help track new IP developments in the stem cell space.

StemCellPatentWatch delivers on a simple premise: It scans new patent grants for those covering stem cell technologies. Complete details on inventorship, patent ownership, and claims are included. You can also use the search form to find patents of interest, and there is a weekly newsletter featuring the patent updates.

I look forward to your feedback on this new site, and for suggestions for further improvement.

Drug Patent Expirations for May 2014

TradenameApplicantGeneric NamePatent NumberPatent Expiration
RYZOLTPurdue Pharmatramadol hydrochloride6,254,887May 10, 2014
RYZOLTPurdue Pharmatramadol hydrochloride5,591,452May 10, 2014
TRITECGlaxosmithklineranitidine bismuth citrate5,629,297May 13, 2014
THALOMIDCelgenethalidomide5,629,327May 13, 2014
IMAGENTImcor Pharms Codimyristoyl lecithin; perflexane5,626,833May 16, 2014
RESTASISAllergancyclosporine5,474,979May 17, 2014
CHILDREN'S ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride7,138,524May 18, 2014
CHILDREN'S ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride7,138,524May 18, 2014
RISPERDAL CONSTAJanssen Pharmsrisperidone6,368,632*PEDMay 19, 2014
NATRECORScios Llcnesiritide recombinant5,114,923May 19, 2014
RISPERDAL CONSTAJanssen Pharmsrisperidone6,110,921*PEDMay 19, 2014
RISPERDAL CONSTAJanssen Pharmsrisperidone7,547,452*PEDMay 19, 2014
KALETRAAbbvielopinavir; ritonavir5,886,036*PEDMay 19, 2014
RISPERDAL CONSTAJanssen Pharmsrisperidone5,965,168*PEDMay 19, 2014
LUPRON DEPOTAbbvie Endocrine Incleuprolide acetate5,631,020May 20, 2014
LUPRON DEPOTAbbvie Endocrine Incleuprolide acetate5,631,021May 20, 2014
ZINGOPowder Pharmslidocaine hydrochloride5,630,796May 20, 2014
LUPRON DEPOT-PEDAbbvie Endocrine Incleuprolide acetate5,631,020May 20, 2014
INOMAXInonitric oxide5,558,083*PEDMay 22, 2014
TAXOTERESanofi Aventis Usdocetaxel5,438,072*PEDMay 22, 2014
COPAXONETeva Pharms Usaglatiramer acetate6,342,476May 24, 2014
COPAXONETeva Pharms Usaglatiramer acetate5,981,589May 24, 2014
COPAXONETeva Pharms Usaglatiramer acetate6,054,430May 24, 2014
COPAXONETeva Pharms Usaglatiramer acetate8,367,605May 24, 2014
COPAXONETeva Pharms Usaglatiramer acetate6,620,847May 24, 2014
COPAXONETeva Pharms Usaglatiramer acetate6,362,161May 24, 2014
COPAXONETeva Pharms Usaglatiramer acetate7,199,098May 24, 2014
COPAXONETeva Pharms Usaglatiramer acetate6,939,539May 24, 2014
MALARONEGlaxosmithklineatovaquone; proguanil hydrochloride6,166,046*PEDMay 25, 2014
MALARONE PEDIATRICGlaxosmithklineatovaquone; proguanil hydrochloride5,998,449*PEDMay 25, 2014
MALARONE PEDIATRICGlaxosmithklineatovaquone; proguanil hydrochloride6,291,488*PEDMay 25, 2014
MALARONEGlaxosmithklineatovaquone; proguanil hydrochloride5,998,449*PEDMay 25, 2014
MALARONEGlaxosmithklineatovaquone; proguanil hydrochloride6,291,488*PEDMay 25, 2014
MALARONE PEDIATRICGlaxosmithklineatovaquone; proguanil hydrochloride6,166,046*PEDMay 25, 2014
ALLEGRASanofi Aventis Usfexofenadine hydrochloride5,578,610*PEDMay 26, 2014
CHILDREN'S ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride5,578,610*PEDMay 26, 2014
ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride5,578,610*PEDMay 26, 2014
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONSanofi Aventis Usfexofenadine hydrochloride; pseudoephedrine hydrochloride5,578,610*PEDMay 26, 2014
NAROPINFresenius Kabi Usaropivacaine hydrochloride5,834,489May 26, 2014
CHILDREN'S ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride5,578,610*PEDMay 26, 2014
ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride5,578,610*PEDMay 26, 2014
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTIONSanofi Aventis Usfexofenadine hydrochloride; pseudoephedrine hydrochloride5,578,610*PEDMay 26, 2014
SPORANOXJanssen Pharmsitraconazole5,633,015May 27, 2014
NEXIUM IVAstrazenecaesomeprazole sodium6,143,771May 27, 2014
NORDITROPINNovo Nordisk Incsomatropin recombinant5,633,352May 27, 2014
RECTIVAptalis Pharmanitroglycerin7,189,761May 27, 2014
CELEBREXGd Searlecelecoxib5,563,165*PEDMay 30, 2014
CELEBREXGd Searlecelecoxib5,466,823*PEDMay 30, 2014
ERTACZOValeant Luxembourgsertaconazole nitrate5,135,943May 31, 2014
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Strategic alliances as a mechanism for wealth creation in the biopharmaceutical industry: An empirical analysis of the Spanish case

Go to paper

ABSTRACT: The paper studies strategic alliances signed between traditional pharmaceutical companies (TPCs) and new biotechnology firms (NBFs) in Spain, on the initial basis that a firm's rate of new product development is a positive function of the number of strategic alliances that it has entered into. Nevertheless, we believe, as do others, that although strategic alliances may initially have positive effects on that rate, this relationship may exhibit diminishing returns...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website